Université de Lille, Inserm, CHU Lille, CIC 1403 - Clinical Investigation Center, 59000 Lille, France.; F-CRIN IREIVAC/COVIREIVAC, 75679 Paris, France.
F-CRIN IREIVAC/COVIREIVAC, 75679 Paris, France; Université de Paris, Inserm CIC 1417, Assistance publique - Hôpitaux de Paris, hôpital Cochin, 75679 Paris, France.
Therapie. 2021 Jul-Aug;76(4):277-283. doi: 10.1016/j.therap.2021.05.004. Epub 2021 May 12.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread around the globe leading to the COVID-19 pandemic. To mitigate the effects of the virus on public health and the global economy, vaccines were rapidly developed. In less than one year, with respect to usual clinical development rules, several vaccines have been put on the market and mass vaccination campaigns have been deployed. During the phase I to phase III clinical trials, most of these vaccines have demonstrated both their safety and efficacy. Despite questions remain about the impact of virus variants and the duration of the immune response, messenger RNA (mRNA)-based and adenoviral vectored vaccines have demonstrated an overall efficacy from 70 to 95% in both phase III trials and real life. In addition, all these vaccines also reduce the severe forms of the disease and might strongly impact the mortality which could change the course of the pandemic.
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）在全球迅速传播，导致 COVID-19 大流行。为了减轻病毒对公众健康和全球经济的影响，疫苗被迅速开发。不到一年的时间，按照通常的临床开发规则，几种疫苗已经投放市场，并开展了大规模疫苗接种运动。在 I 期至 III 期临床试验中，这些疫苗大多数都证明了它们的安全性和有效性。尽管关于病毒变异和免疫反应持续时间的问题仍然存在，但信使 RNA（mRNA）疫苗和腺病毒载体疫苗在 III 期临床试验和真实世界中均显示出 70%至 95%的总体有效性。此外，所有这些疫苗还可减轻疾病的严重程度，并可能对死亡率产生重大影响，从而改变大流行的进程。
